Drugs / Flumatinib
Trials 10
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-06-12 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results EHA 2026 | HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML) hspharm.com ↗
At week 48, MMR achieved 80% and MR4.0 was 30%. |
| 2025-12-19 | Hansoh BioMedical R&D Company | Results 2025 ASH | 翰森制药创新药豪森昕福®携多项创新研究亮相，为国际血液肿瘤前沿研究注入中国创新动能 hansoh.cn ↗
结果显示，在6个月、12个月和24个月时，氟马替尼组和尼洛替尼组的完全细胞遗传学反应（CCyR）、主要分子学反应（MMR）、分子学反应4. 0（MR4. 0）和分子学反应4. 5（MR4. 5）的累积发生率均无统计学显著差异. |
| 2024-11-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory FOUR INNOVATIVE DRUGS OF HANSOH PHARMACEUTICAL GROUP HAVE BEEN RENEWED IN THE NATIONAL REIMBURSEMENT DRUG LIST (2024 VERSION) hspharm.com ↗ |
| 2024-09-20 | Hansoh BioMedical R&D Company | Results 2024 ESMO | 翰森制药创新药氟马替尼治疗新诊断成人Ph+ ALL成果荣登国际学术大会 hansoh.cn ↗
在氟马替尼联合多药化疗后，诱导的完全缓解（CR）率在0. 5个月、1个月、3个月、6个月分别达到100%、97. 9%、100%和93. 3%. |
| 2023-01-18 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA'S SEVERAL INNOVATIVE DRUGS AND NEW INDICATIONS WERE ADDED TO THE 2022 NATIONAL REIMBURSEMENT DRUG LIST hspharm.com ↗
Hansoh Pharma's first Chinese original chronic myeloid leukemia (CML) drug Hansoh Xinfu (Flumatinib Mesylate Tablets) and first Chinese original long-acting GLP-1 hypoglycemic drug Fulaimei (Polyethylene Glycol Loxenatide Injection) have been successfully renewed in the National Reimbursement Drug List through negotiation. |
| 2021-04-17 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results GOLD SHINES BRIGHTER AFTER COMING OUT FROM FIRE丨HANSOH XINFU'S REAL-WORLD CLINICAL EFFECT IS HIGHLY RECOGNIZED hspharm.com ↗
The data showed that Hansoh Xinfu has significant clinical efficacy. |
| 2020-12-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory PROMISING PROSPECTS: HANSOH PHARMA'S CLASS 1 INNOVATIVE DRUGS, AMEILE, HANSOH XINFU AND FULAIMEI, INCLUDED IN CHINA’S NATIONAL REIMBURSEMENT DRUG LIST hspharm.com ↗
Hansoh Pharma's Ameile (Almonertinib Mesylate Tablets), Hansoh Xinfu (Flumatinib Mesylate Tablets) and Fulaimei (Polyethylene Glycol Loxenatide Injection) are included. |
All press releases naming this drug 9 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flumatinib | “Doses are halved/reduced per protocol: Flumatinib 400/200 mg QD, Imatinib 200 mg QD, Nilotinib 300 mg QD, Dasatinib 50 mg QD, or Olverembatinib 20 mg QD, based on pre-entry therapy.” NCT07839988 ↗ |
| Action | Inhibit | “Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib.” PMID 32928796 ↗ Sep 2020 |
| Modality | Small molecule | “Flumatinib is the first approved second generation TKI in China and a derivative of imatinib.” NCT04375683 ↗ |
| Route | Oral | “The starting daily oral dose of Flumatinib is 600mg” NCT02511340 ↗ |
| Target | ABL1 | “Flumatinib, a TKI with more potent binding affinity for BCR-ABL1 tyrosine kinase than imatinib” NCT05071482 ↗ |